<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04690088</url>
  </required_header>
  <id_info>
    <org_study_id>BEC - MF - 93</org_study_id>
    <nct_id>NCT04690088</nct_id>
  </id_info>
  <brief_title>Remifentanil Dosing Regimes for Anesthesia in Bariatric Surgery: Characteristics of Early Recovery</brief_title>
  <official_title>Remifentanilio Titravimo būdų Palyginimas, Remiantis pacientų Budimo Kokybe Ligotai Nutukusiems Pacientams po laparoskopinių skrandžio tūrio mažinimo operacijų</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lithuanian University of Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lithuanian University of Health Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Early recovery characteristics are important for patients' safety and operating room&#xD;
      turnover. Our aim was to compare fundamental methods for dosing remifentanil during morbid&#xD;
      obesity surgeries: a manual infusion and a target-controlled infusion (TCI). Throughout&#xD;
      study, patient's recovery time was tracked and compared between the groups.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Introduction: The population of overweighted patients is increasing dramatically, therefore&#xD;
      physicians face them in their daily practice (1-2). There are many guidelines showing the&#xD;
      dose counting methods of intravenous anesthetics, but none of them are perfectly good for&#xD;
      morbidity obese patients (3). Early recovery characteristics are important for patients'&#xD;
      safety and operating room turnover (4).&#xD;
&#xD;
      Aim: Our aim was to compare fundamental methods for dosing remifentanil during morbid obesity&#xD;
      surgeries: a manual infusion and a target-controlled infusion (TCI). Throughout study,&#xD;
      patient's recovery time was tracked and compared between the groups.&#xD;
&#xD;
      Methods: 31 patients were evaluated who underwent bariatric surgery in Hospital of Lithuanian&#xD;
      University of Health Sciences. All of them had received sevoflurane/remifentanil anaesthesia.&#xD;
      Remifentanil infusion was randomly assigned to a manual (control group) or to a TCI (case&#xD;
      group) method. We had evaluated patients' hemodynamics (arterial blood pressure, heart rate,&#xD;
      saturation), spontaneous breathing and airway reflexes recovery time, time of extubation, eye&#xD;
      opening, recovery of orientation and start of the following oral command. Also we had&#xD;
      registered concentrations of remifentanil in the blood (according to automatic infusion pump)&#xD;
      while using TCI method.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 10, 2019</start_date>
  <completion_date type="Actual">February 10, 2020</completion_date>
  <primary_completion_date type="Actual">December 1, 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>4 Months</target_duration>
  <primary_outcome>
    <measure>eye opening</measure>
    <time_frame>up to 20 minutes</time_frame>
    <description>The time of patient's respond after the end of remifentanyl infusion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>spontaneous breathing</measure>
    <time_frame>up to 20 minutes</time_frame>
    <description>The time of patient's respond after the end of remifentanyl infusion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>airway reflexes</measure>
    <time_frame>up to 20 minutes</time_frame>
    <description>The time of patient's respond after the end of remifentanyl infusion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>orientation</measure>
    <time_frame>up to 20 minutes</time_frame>
    <description>The time of patient's respond after the end of remifentanyl infusion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>oral command</measure>
    <time_frame>2,4,6,8,10,12,14,16,18,20 minutes</time_frame>
    <description>The time of patient's respond after the end of remifentanyl infusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>up to 20 minutes</time_frame>
    <description>Measure was started after the end of remifentanyl infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial blood pressure</measure>
    <time_frame>up to 20 minutes</time_frame>
    <description>Measure was started after the end of remifentanyl infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Saturation</measure>
    <time_frame>up to 20 minutes</time_frame>
    <description>Measure was started to record after the end of remifentanyl infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Remifentanyl dose</measure>
    <time_frame>up to 20 minutes after surgery</time_frame>
    <description>The amount of medication used during surgery</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">31</enrollment>
  <condition>Morbid Obesity</condition>
  <arm_group>
    <arm_group_label>Manual infusion (control) group</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>TCI (case) group</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with morbid obesity who are hospitalised in Hospital of Lithuanian University of&#xD;
        Health Sciences Kaunas Clinics for laparoscopic bariatric surgery.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Morbid patients to whom, according guidelines (BMI &gt; 45 or BMI &gt; 35 and chronic&#xD;
             disease) bariatric surgery is indicated.&#xD;
&#xD;
          -  Patient's approval.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients, younger than 18 years old.&#xD;
&#xD;
          -  Patients who are higher than III ASA class.&#xD;
&#xD;
          -  Patients who have higher sensibility to medications that are used during anesthesia.&#xD;
&#xD;
          -  Patients with phycological disorders.&#xD;
&#xD;
          -  Patients who can not fully communicate because of language barriers.&#xD;
&#xD;
          -  Patients with surgical complications.&#xD;
&#xD;
          -  Patient's disapproval.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>28 Years</minimum_age>
    <maximum_age>57 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Lithuanian University of Health Sciences</name>
      <address>
        <city>Kaunas</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Lithuania</country>
  </location_countries>
  <link>
    <url>http://ncdrisc.org/morbid-obesity-prevalence-ranking.html</url>
    <description>Body - Mass index. Evaluation of BMI over time.</description>
  </link>
  <link>
    <url>https://www.ovid.com/product-details.496.html</url>
    <description>Cortrnez L I, Anderson B J. Current Opinion in Anaesthesiology 2018; 31(4):415-422.</description>
  </link>
  <link>
    <url>https://link.springer.com/article/10.2165/00003088-199529020-00003</url>
    <description>Egan T D. Remyfentanil Pharmacocinetics and Pharmacodynamics. Clin. Pharmacokinet 1995; 29:80.</description>
  </link>
  <link>
    <url>https://vapris.vvkt.lt/vvkt-web/public/medications/view/20375</url>
    <description>Valstybinė vaistų kontrolės tarnyba. Remifentanil Kabi.</description>
  </link>
  <reference>
    <citation>Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults--The Evidence Report. National Institutes of Health. Obes Res. 1998 Sep;6 Suppl 2:51S-209S. Review. Erratum in: Obes Res 1998 Nov;6(6):464.</citation>
    <PMID>9813653</PMID>
  </reference>
  <reference>
    <citation>Cheymol G. Effects of obesity on pharmacokinetics implications for drug therapy. Clin Pharmacokinet. 2000 Sep;39(3):215-31. Review.</citation>
    <PMID>11020136</PMID>
  </reference>
  <reference>
    <citation>Adams JP, Murphy PG. Obesity in anaesthesia and intensive care. Br J Anaesth. 2000 Jul;85(1):91-108. Review.</citation>
    <PMID>10927998</PMID>
  </reference>
  <reference>
    <citation>Michelsen LG, Hug CC Jr. The pharmacokinetics of remifentanil. J Clin Anesth. 1996 Dec;8(8):679-82. Review.</citation>
    <PMID>8982900</PMID>
  </reference>
  <reference>
    <citation>Egan TD, Kern SE, Muir KT, White J. Remifentanil by bolus injection: a safety, pharmacokinetic, pharmacodynamic, and age effect investigation in human volunteers. Br J Anaesth. 2004 Mar;92(3):335-43.</citation>
    <PMID>14970134</PMID>
  </reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>October 8, 2020</study_first_submitted>
  <study_first_submitted_qc>December 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 30, 2020</study_first_posted>
  <last_update_submitted>December 28, 2020</last_update_submitted>
  <last_update_submitted_qc>December 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lithuanian University of Health Sciences</investigator_affiliation>
    <investigator_full_name>Paulina Aldakauskaite</investigator_full_name>
    <investigator_title>resident doctor</investigator_title>
  </responsible_party>
  <keyword>morbid obesity</keyword>
  <keyword>remifentanil</keyword>
  <keyword>manual infusion</keyword>
  <keyword>target - controlled infusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity, Morbid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

